[11] These comprise inotuzumab ozogamicin (anti-CD22 monoclonal antibody (mAb) conjugated with calicheamicin), [13–15] anti-CD19 CAR-T, [3] and blinatumomab (CD19xCD3 BiTE), [2] which was recently approved for consolidation therapy in pediatric and adult patients with Philadelphia chromosome (Ph)-negative ALL. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.